Dr. Hornick’s research focus is the relationship between cutaneous immune-related adverse events (occurring in the context of checkpoint therapy) and naturally-occurring inflammatory skin diseases. His work leverages transcriptomic and protein-level methodologies to explore these relationships, and he has a particular interest in relating mechanisms underlying diseases to the broadening of the applicability of existing therapeutics